Risultati della ricerca - Stål, Olle

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and b... di Hilborn, Erik, Stål, Olle, Jansson, Agneta

Testo Testo Testo

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breas... di Hilborn, Erik, Stål, Olle, Alexeyenko, Andrey, Jansson, Agneta

Testo Testo Testo

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer di Busch, Susann, Rydén, Lisa, Stål, Olle, Jirström, Karin, Landberg, Göran

Testo Testo Testo

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer di Wegman, Pia, Elingarami, Sauli, Carstensen, John, Stål, Olle, Nordenskjöld, Bo, Wingren, Sten

Testo Testo Testo

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients di Hilborn, Erik, Sivik, Tove, Fornander, Tommy, Stål, Olle, Nordenskjöld, Bo, Jansson, Agneta

Testo Testo Testo

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer di Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle

Testo Testo Testo

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer di Karlsson, Elin, Veenstra, Cynthia, Gårsjö, Jon, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle

Testo Testo Testo

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer di Jerevall, Piiha-Lotta, Jansson, Agneta, Fornander, Tommy, Skoog, Lambert, Nordenskjöld, Bo, Stål, Olle

Testo Testo Testo

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer di Sivik, Tove, Gunnarsson, Cecilia, Fornander, Tommy, Nordenskjöld, Bo, Skoog, Lambert, Stål, Olle, Jansson, Agneta

Testo Testo Testo

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer di Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle

Testo Testo Testo

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer di Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle

Testo Testo Testo

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients di Wegman, Pia, Vainikka, Linda, Stål, Olle, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars-Erik, Wingren, Sten

Testo Testo Testo

Exploring cancer register data to find risk factors for recurrence of breast cancer – application of Canonical Correlation Analysis di Razavi, Amir R, Gill, Hans, Stål, Olle, Sundquist, Marie, Thorstenson, Sten, Åhlfeldt, Hans, Shahsavar, Nosrat

Testo Testo Testo

Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer di Lundgren, Katja, Tobin, Nicholas P., Lehn, Sophie, Stål, Olle, Rydén, Lisa, Jirström, Karin, Landberg, Göran

Testo Testo Testo

Akt kinases in breast cancer and the results of adjuvant therapy di Stål, Olle, Pérez-Tenorio, Gizeh, Åkerberg, Linda, Olsson, Birgit, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars Erik

Testo Testo

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response di Lehn, Sophie, Tobin, Nicholas P, Sims, Andrew H, Stål, Olle, Jirström, Karin, Axelson, Håkan, Landberg, Göran

Testo Testo Testo

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer di Schroeder, Brock, Zhang, Yi, Stål, Olle, Fornander, Tommy, Brufsky, Adam, Sgroi, Dennis C., Schnabel, Catherine A.

Testo Testo Testo

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer di Bostner, Josefine, Alayev, Anya, Berman, Adi Y., Fornander, Tommy, Nordenskjöld, Bo, Holz, Marina K., Stål, Olle

Testo Testo Testo

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype di Veenstra, Cynthia, Karlsson, Elin, Mirwani, Sanam Mirwani, Nordenskjöld, Bo, Fornander, Tommy, Pérez-Tenorio, Gizeh, Stål, Olle

Testo Testo Testo

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit di Bostner, Josefine, Karlsson, Elin, Pandiyan, Muneeswaran J., Westman, Hanna, Skoog, Lambert, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle

Testo Testo Testo